BDX Reports Operations, Officer Changes, and Financials

Ticker: BDX · Form: 8-K · Filed: Oct 15, 2025 · CIK: 10795

Sentiment: neutral

Topics: operations, officer-changes, debt, financial-statements

Related Tickers: BDX

TL;DR

BDX filed an 8-K on Oct 9, 2025, detailing operations, exec changes, and debt like $1.9B notes due Dec 2026.

AI Summary

Becton, Dickinson and Company (BDX) filed an 8-K on October 15, 2025, reporting on results of operations, changes in officers, and financial statements. The filing covers events as of October 9, 2025, and includes details on various debt instruments, such as $1.900 billion in notes due December 15, 2026, and $1.208 billion in notes due June 4, 2026.

Why It Matters

This 8-K filing provides investors with crucial updates on Becton Dickinson's operational performance, executive team changes, and financial health, including significant debt obligations.

Risk Assessment

Risk Level: medium — The filing includes information on debt issuances and potential changes in executive leadership, which can introduce operational and financial risks.

Key Numbers

Key Players & Entities

FAQ

What specific results of operations are being reported as of October 9, 2025?

The filing indicates 'Results of Operations and Financial Condition' as an item reported, but the specific details of these results are not provided in the header information.

Who are the specific officers or directors whose departure or election is being reported?

The filing lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item, but the names of the individuals involved are not detailed in the provided header.

What is the purpose of the Regulation FD Disclosure mentioned in the filing?

Regulation FD Disclosure is an item reported, indicating that the company is making public disclosures to prevent selective disclosure of material non-public information.

What are the maturity dates for the $1.900 billion and $1.208 billion notes?

The $1.900 billion notes are due December 15, 2026, and the $1.208 billion notes are due June 4, 2026.

What is the SIC code for Becton, Dickinson and Company?

The Standard Industrial Classification (SIC) code for Becton, Dickinson and Company is 3841, which corresponds to 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS'.

Filing Stats: 1,077 words · 4 min read · ~4 pages · Grade level 10 · Accepted 2025-10-15 16:18:58

Key Financial Figures

Filing Documents

02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On October 15, 2025, Becton, Dickinson and Company (the "Company") issued a press release announcing its preliminary unaudited revenue for its fourth quarter and full fiscal year ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles ("non-GAAP measures"). Details regarding these non-GAAP measures and adjustments can be found in the schedules included in the press release furnished as Exhibit 99.1. The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. On October 9, 2025, Christopher J. DelOrefice informed Becton, Dickinson and Company (the "Company" or "BD") of his intention to resign from his position as the Company's Executive Vice President and Chief Financial Officer effective December 5, 2025 to pursue a new professional opportunity. Mr. DelOrefice will remain in his current role with the Company until his departure. Mr. DelOrefice's departure is not the result of any disagreement with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices. In connection with Mr. DelOrefice's departure from the position of Chief Financial Officer, Vitor Roque, Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis, has been appointed by the Company's Board of Directors to act as the Company's interim Chief Financial Officer, effective upon Mr. DelOrefice's departure, until a permanent successor is named. In this role, Mr. Roque will serve as the Company's principal financial officer. The Company has a search underway to identify a permanent Chief Financial Officer. Mr. Roque, age 43, has served as the Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis at the Company since September 2024. In this role, he oversees the financial operations across all BD business units and leads the central capability for segment strategic support and financial planning and analysis. Prior to his current role, he held key positions at BD, including Vice President and CFO of BD Medical Segment from July 2021 through November 2024 and Vice President of Finance for Medication Management Solutions from January 2019 through August 2021. Mr. Roque brings more than 20 years of global finance and leadership experience. Information referred to in Item 5.02(c)(3) of Form

01 REGULATION FD DISCLOSURE

ITEM 7.01 REGULATION FD DISCLOSURE. On October 15, 2025, the Company issued a press release relating to the matters described above in Item 5.02. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and Exhibit 99.1 shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. Exhibit 99 .1 Press release dated October 15, 2025, which is furnished pursuant to Item 2.02 and Item 7.01. Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BECTON, DICKINSON AND COMPANY (Registrant) By: /s/ Stephanie M. Kelly Stephanie M. Kelly Chief Securities and Governance Counsel, Corporate Secretary Date: October 15, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing